ERAS

Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Photronics, Inc. (NASDAQ: PLAB); and Via Transportation, Inc. (NYSE: VIA): Grabar Law Office is Investigating Claims on Your Behalf

Erasca Governance Probe Over ERAS-0015 Disclosures and IP Risk

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Grabar Law Office announced a fiduciary-duty investigation into Erasca over ERAS-0015 statements and risk disclosures, including IP concerns with RMC-6236. April 27, 2026 disclosures noted patent/trade-secret issues and a death from pneumonitis, prompting a stock decline. The outcome could influence governance actions, potential damages, and ERAS-0015&#039;s development timeline.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Grabar Law opens Erasca fiduciary-duty probe. Reviews ERAS-0015 disclosures and oversight.</li><li>April 2026 disclosures cite patent/trade-secret issues. Also report pneumonitis-related death.</li><li>ERAS stock declined after disclosures; governance actions could affect value.</li><li>Shareholders may pursue reforms, damages, and court-approved incentive awards.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Erasca, Inc. (ERAS)</strong>: Subject of fiduciary-duty probe; governance and disclosure risks could impact ERAS-0015 program.</li><li><strong>Revolution Medicines, Inc. (RMC)</strong>: Referenced in ERAS-0015 disclosures; IP/trade-secret risk around comparisons may affect ERAS communications.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Legal; the piece centers on fiduciary-duty investigations and potential securities-related actions, which directly influence ERAS&#039;s governance risk and valuation outlook.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Grabar Law probe likely adds near-term ERAS volatility.</li><li>ERAS-0015 data and IP risk timing could affect partnerships.</li><li>April 2026 disclosures triggered a price drop; catalysts needed for recovery.</li><li>Overall biotech risk sentiment may amplify ERAS moves.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ERAS ticker: NASDAQ ERAS.</li><li>ERAS-0015 is a pan-RAS molecular glue candidate for solid tumors.</li><li>April 27, 2026: Erasca disclosed patent/trade-secret issues with Revolution Medicines and a pneumonitis-related death.</li><li>ERAS share price declined following the disclosures.</li><li>Grabar Law Office announced a shareholder investigation into ERAS.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Over the next 3–6 months, ERAS could remain volatile on governance headlines; a favorable settlement or stronger data could unlock upside.</p>
  </section>
</section>


<article>
  <p>PHILADELPHIA , July  21, 2026  (GLOBE NEWSWIRE) --</p>

  <section>
    <h2><strong><u>ERASCA, INC. (NASDAQ:<a href="https://www.benzinga.com/quote/ERAS">ERAS</a>):</u></strong></h2>

    <p>Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ:<a href="https://www.benzinga.com/quote/ERAS">ERAS</a>) (<em>Erasca</em> or the <em>Company</em>>) breached their fiduciary duties owed to the Company and its shareholders.</p>

    <section>
      <h3>What is This Investigation About?</h3>
      <p>The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.</p>
    </section>

    <section>
      <h3>Shareholder Eligibility and How to Seek Relief</h3>
      <p><strong>If you are a current Erasca (NASDAQ:<a href="https://www.benzinga.com/quote/ERAS">ERAS</a>) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit</strong> 
      <a href="https://www.globenewswire.com/Tracker?data=S5waOV-VrTXibz3jrx7rVbaLfvjashrwdmGPuet3v2UXj7f0S-s1ZKoLUU-Urz4I1knGij1hBIJk_NFcOZvuW4dR46G0jTXfC36zpa8DxvO0Xi07q_8Oseur-7y7EzGc8K-5iJ73bXor_JzLltTFhAIvvDlQBdvDDMr_bEjFCQaD7Fg5MQNn7dZJUygmSLycf-QaxwnQveK6gOXNt5Clvg=="
      rel="nofollow" target="_blank"><strong>https://grabarlaw.com/the-latest/erasca-shareholder-investigation/</strong></a><strong>, </strong><strong>contact Joshua H. Grabar at </strong>
      <a href="https://www.globenewswire.com/Tracker?data=5kcdh9QsfVvOaczLoOfJOBBpGiK2wutZSrsIdM3Eg-h5qCLOcyWR4J0PzA1CGO_ghVP5clz7iWMtDDiZZutj2n9yUa7Wkd5puJTkrSnA084="
      rel="nofollow" target="_blank"><strong>jgrabar@grabarlaw.com</strong></a><strong>, or call us at 267-507-6085.</strong></p>
    </section>

    <section>
      <h3>What is Alleged?</h3>
      <p>According to a recently filed federal securities class action, investors allege that Erasca made materially misleading statements and omissions concerning ERAS-0015. Among other things, the complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential <em>"best-in-class"</em> therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines' RMC-6236; the Company's public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis.</p>
    </section>

    <section>
      <h3>April 2026 Disclosures</h3>
      <p><strong>April 27, 2026</strong> Disclosures: On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited. Following these disclosures, Erasca's share price experienced a substantial decline.</p>
    </section>

    <section>
      <h3>What Can You Do Now?</h3>
      <p><strong>If you are a current Erasca (NASDAQ:<a href="https://www.benzinga.com/quote/ERAS">ERAS</a>) shareholder and have held shares since prior to January 14, 2025, you can seek corporate governance reforms, damages on behalf of the Company, and other relief through a shareholder derivative action including a court approved incentive award. Please visit</strong>
      <a href="https://www.globenewswire.com/Tracker?data=S5waOV-VrTXibz3jrx7rVbaLfvjashrwdmGPuet3v2UXj7f0S-s1ZKoLUU-Urz4I1knGij1hBIJk_NFcOZvuW-hgWob3cNCcJSGLUIPB1bxaXY5YufEAL7XaxfTl3jj81kTRmcy5VElLBgeMMhLua0ECHbXZSxECTOcFGF_1puI-Z_XJPf4TGqOx16IOO0ZH4K6W6xUYFU7tK3Lyp64i0w=="
      rel="nofollow" target="_blank"><strong>https://grabarlaw.com/the-latest/erasca-shareholder-investigation/</strong></a><strong>, </strong><strong>contact Joshua H. Grabar at </strong>
      <a href="https://www.globenewswire.com/Tracker?data=5kcdh9QsfVvOaczLoOfJOBBpGiK2wutZSrsIdM3Eg-jiSm3guoReVOtKYC35nTM3_I6_jvqak1eQBfW9aaOtM97DedtvODKU3QKM0Lx5w18=" rel="nofollow" target="_blank"><strong>jgrabar@grabarlaw.com</strong></a><strong>, or call us at 267-507-6085. </strong>#Erasca #ERAS $ERAS</p>
    </section>
  </section>

  <section>
    <h2><strong><u>INSULET CORPORATION (NASDAQ: PODD):</u></strong></h2>

    <p>Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ:<a href="https://www.benzinga.com/quote/PODD">PODD</a>).</p>

    <section>
      <h3>What Is This Investigation About?</h3>
      <p>The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.</p>
    </section>

    <section>
      <h3>What If You Purchased Insulet Shares?</h3>
      <p><strong>If you purchased Insulet Corporation (NASDAQ:<a href="https://www.benzinga.com/quote/PODD">PODD</a>)</strong> <strong>shares prior to February 21, 2025</strong><strong>,</strong> <strong>and still hold shares today,</strong> <strong>you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.</strong> <strong>Please visit</strong> 
      <a href="https://www.globenewswire.com/Tracker?data=S5waOV-VrTXibz3jrx7rVbaLfvjashrwdmGPuet3v2VnLW65xKlInr61InLZMmcmBVMbgwkHjLOfFGph2Wr7aWRQt52LA-OQZc2K0snsnEqdcIFKKXWmd9lb3_Ma9mugrofEwpjgGGH6hT4bXLrttYVsTRWSF5NqrguFlQf1q2DXOHiSs6gSNKaoffWa79QjQFKSNwke3Bgz1JLaElC-LWjGv2XRUcwHUsT0cjVsPFs=" rel="nofollow" target="_blank"><strong>https://grabarlaw.com/the-latest/insulet-shareholder-investigation/</strong></a><strong>, </strong><strong>contact Joshua Grabar at </strong>
      <a href="https://www.globenewswire.com/Tracker?data=5kcdh9QsfVvOaczLoOfJOBBpGiK2wutZSrsIdM3Eg-id_HIzO_u3udcgU4Kn8dtCblII564Pdp0RcECh67zw7gKEdaycntoopVw9wkkPyqI=" rel="nofollow" target="_blank"><strong>jgrabar@grabarlaw.com</strong></a><strong>, </strong><strong>or call 267-507-6085. </strong></p>
    </section>

    <section>
      <h3>What Is Alleged?</h3>
      <p>As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ:<a href="https://www.benzinga.com/quote/PODD">PODD</a>), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.</p>

      <p>The truth began to emerge on March 12, 2026, when Insulet disclosed that it had <em>"initiated a voluntary Medical Device Correction for specific lots of Omnipod&amp;reg; 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."</em> Then, on May 26, 2026, Insulet disclosed the <em>"initat[ion]"</em> of another <em>"voluntary Medical Device Correction"</em> (the <em>"May 2026 MDC"</em>), this time ...</p>
    </section>
  </section>
</article>

Grabar Law Office announced a fiduciary-duty investigation into Erasca over ERAS-0015 statements and risk disclosures, including IP concerns with RMC-6236. April 27, 2026 disclosures noted patent/trade-secret issues and a death from pneumonitis, prompting a stock decline. The outcome could influence governance actions, potential damages, and ERAS-0015's development timeline.

notice-to-long-term-shareholders-of-erasca-inc-nasdaq-eras-insulet-corporation-nasdaq-podd-photronics-inc-nasdaq-plab-and-via-transportation-inc-nyse-via-grabar-law-office-is-investigating-claims-on-your-behalf

Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Photronics, Inc. (NASDAQ: PLAB); and Via Transportation, Inc. (NYSE: VIA): Grabar Law Office is Investigating Claims on Your Behalf

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News